# EDGAR Filing Document

**Accession Number:** 0001836379
**File Stem:** 0000000000-23-001022
**Filing Date:** 2023-2
**Character Count:** 3246
**Document Hash:** 9ee4c593c87ea5ffd516588e2e44cc14
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001022.hdr.sgml**: 20230324

**ACCESSION NUMBER**: 0000000000-23-001022

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230201

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VectivBio Holding AG
- **CENTRAL INDEX KEY:** 0001836379
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** AESCHENVORSTADT 36
- **CITY:** BASEL
- **STATE:** V8
- **ZIP:** 4051
- **BUSINESS PHONE:** 41 61 551 30 30

**MAIL ADDRESS:**
- **STREET 1:** AESCHENVORSTADT 36
- **CITY:** BASEL
- **STATE:** V8
- **ZIP:** 4051
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-23-017769

## Text-Extract

```

United States securities and exchange commission logo

                          February 1, 2023

       Luca Santarelli
       Chief Executive Officer
       VectivBio Holding AG
       60 Broad St., Suite 3502
       New York, NY 10004

                                                        Re: VectivBio Holding
AG
                                                            Registration
Statement on Form F-3
                                                            Filed January 27,
2023
                                                            File No. 333-269450

       Dear Luca Santarelli:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jason
Drory at 202-551-8342 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Brandon Fenn

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 1, 2023

Luca Santarelli
Chief Executive Officer
VectivBio Holding AG
60 Broad St., Suite 3502
New York, NY 10004

**Re: VectivBio Holding AG**
**Registration Statement on Form F-3**
**Filed January 27, 2023**
**File No. 333-269450**

Dear Luca Santarelli:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Brandon Fenn